Published in Retrovirology on February 06, 2014
The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol (2014) 1.32
HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J Virol (2014) 1.19
Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. J Virol (2014) 1.10
Counteraction of the multifunctional restriction factor tetherin. Front Microbiol (2014) 1.09
Envelope Glycoprotein Internalization Protects Human and Simian Immunodeficiency Virus-Infected Cells from Antibody-Dependent Cell-Mediated Cytotoxicity. J Virol (2015) 1.01
Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1. Elife (2014) 0.99
Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun (2016) 0.95
Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses. J Virol (2014) 0.89
Critical role for bone marrow stromal antigen 2 in acute Chikungunya virus infection. J Gen Virol (2014) 0.86
Serine Phosphorylation of HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors. PLoS Pathog (2015) 0.85
NK Cells in HIV Disease. Curr HIV/AIDS Rep (2016) 0.84
Modest attenuation of HIV-1 Vpu alleles derived from elite controller plasma. PLoS One (2015) 0.81
Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1 Entry Receptors. J Virol (2015) 0.79
HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites. J Virol (2016) 0.79
The role of BST-2/Tetherin in host protection and disease manifestation. Immun Inflamm Dis (2015) 0.79
Bone marrow stromal antigen 2 (BST-2) DNA is demethylated in breast tumors and breast cancer cells. PLoS One (2015) 0.79
Vpu Protein: The Viroporin Encoded by HIV-1. Viruses (2015) 0.78
Novel Acylguanidine-Based Inhibitor of HIV-1. J Virol (2016) 0.78
In COS cells Vpu can both stabilize tetherin expression and counteract its antiviral activity. PLoS One (2014) 0.77
Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs. Front Immunol (2015) 0.77
Determinants in HIV-2 Env and tetherin required for functional interaction. Retrovirology (2015) 0.77
A Genetic Screen Identifies a Critical Role for the WDR81-WDR91 Complex in the Trafficking and Degradation of Tetherin. Traffic (2016) 0.77
Remodeling of the Host Cell Plasma Membrane by HIV-1 Nef and Vpu: A Strategy to Ensure Viral Fitness and Persistence. Viruses (2016) 0.77
Tetherin Antagonism by HIV-1 Group M Nef Proteins. J Virol (2016) 0.76
Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains. J Virol (2016) 0.76
Enhancing Virion Tethering by BST2 Sensitizes Productively and Latently HIV-infected T cells to ADCC Mediated by Broadly Neutralizing Antibodies. Sci Rep (2016) 0.76
Conserved residues within the HIV-1 Vpu transmembrane-proximal hinge region modulate BST2 binding and antagonism. Retrovirology (2017) 0.75
Pharmacologic Inhibition of Nedd8 Activation Enzyme Exposes CD4-Induced Epitopes within Env on Cells Expressing HIV-1. J Virol (2015) 0.75
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
Cell-based Fluorescence Complementation Reveals a Role for HIV-1 Nef Dimerization in AP-2 Recruitment and CD4 downregulation. J Biol Chem (2016) 0.75
Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates. J Virol (2016) 0.75
The latest science from the IAS Towards an HIV Cure Symposium: 16-17 July 2016, Durban, South Africa. J Virus Erad (2016) 0.75
HIV-1 Vpu Downmodulates ICAM-1 Expression, Resulting in Decreased Killing of Infected CD4(+) T Cells by NK Cells. J Virol (2017) 0.75
Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG. JCI Insight (2017) 0.75
Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies. J Virol (2017) 0.75
In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach. J Virol Methods (2016) 0.75
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. Cell (2017) 0.75
HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV. J Virol (2017) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature (2008) 14.99
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 11.91
The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe (2008) 9.27
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol (1990) 7.85
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell (1994) 5.92
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med (2009) 5.87
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol (1995) 5.43
Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV. Science (1986) 4.79
Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog (2009) 4.24
Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe (2009) 4.11
Envelope glycoprotein of HIV induces interference and cytolysis resistance in CD4+ cells: mechanism for persistence in AIDS. Cell (1988) 3.12
Characterization of the nuclear and cytoplasmic components of the lymphoid-specific nuclear factor of activated T cells (NF-AT) complex. J Biol Chem (1993) 2.98
CD4 is retained in the endoplasmic reticulum by the human immunodeficiency virus type 1 glycoprotein precursor. J Virol (1990) 2.96
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J Virol (1996) 2.61
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 2.53
Human immunodeficiency virus type 1 Nef-induced down-modulation of CD4 is due to rapid internalization and degradation of surface CD4. J Virol (1994) 2.17
HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog (2007) 2.13
Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog (2010) 2.12
Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol (2013) 1.93
Characterization of recombinant human interleukin-2 with micromethods. J Chromatogr (1985) 1.76
Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe (2010) 1.74
Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog (2010) 1.66
HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood (2009) 1.63
ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog (2012) 1.60
Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A (2011) 1.58
Molecular mechanisms of HIV entry. Adv Exp Med Biol (2012) 1.55
Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. Retrovirology (2007) 1.48
The Nef protein of human immunodeficiency virus establishes superinfection immunity by a dual strategy to downregulate cell-surface CCR5 and CD4. Curr Biol (2005) 1.48
Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses (2002) 1.46
HIV: cell binding and entry. Cold Spring Harb Perspect Med (2012) 1.46
Mechanisms of CD4 downregulation by the Nef and Vpu proteins of primate immunodeficiency viruses. Curr Mol Med (2007) 1.41
In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc Natl Acad Sci U S A (2011) 1.36
Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A (2012) 1.36
Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells. J Biol Chem (2003) 1.33
Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils. PLoS One (2013) 0.95
Efficient BST2 antagonism by Vpu is critical for early HIV-1 dissemination in humanized mice. Retrovirology (2013) 0.90
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med (2006) 13.15
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med (2003) 4.53
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med (2010) 3.81
HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. Immunity (2004) 2.86
Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol (2009) 2.51
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS (2008) 1.89
Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med (2008) 1.85
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol (2002) 1.84
Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J Immunol (2009) 1.79
Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS (2008) 1.63
HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood (2009) 1.63
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS (2004) 1.61
Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection. J Exp Med (2011) 1.60
Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study. J Immunol (2009) 1.52
A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS (2008) 1.47
Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr (2009) 1.46
Memory CCR6+CD4+ T cells are preferential targets for productive HIV type 1 infection regardless of their expression of integrin β7. J Immunol (2011) 1.31
CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog (2012) 1.28
Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J Clin Invest (2011) 1.27
Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood (2013) 1.24
Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL. J Immunol (2005) 1.23
CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. J Clin Virol (2011) 1.21
Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr (2004) 1.19
The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4+ T cells. J Immunol (2007) 1.18
Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine (2011) 1.15
Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L. J Immunol (2005) 1.15
Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection. J Immunol (2013) 1.14
Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57. J Virol (2011) 1.14
Slow disease progression and robust therapy-mediated CD4+ T-cell recovery are associated with efficient thymopoiesis during HIV-1 infection. Blood (2007) 1.13
Oxytocin in cardiac ontogeny. Proc Natl Acad Sci U S A (2004) 1.13
CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission. AIDS (2014) 1.11
Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection. PLoS Pathog (2013) 1.10
A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. AIDS (2011) 1.10
Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease. J Med Virol (2002) 1.10
Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers. PLoS One (2013) 1.08
Decreased levels of circulating IL-21 in HIV-infected AIDS patients: correlation with CD4+ T-cell counts. Viral Immunol (2008) 1.07
A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses. J Immunol Methods (2006) 1.04
Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood (2012) 1.03
Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology (2009) 1.03
HIV infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease. J Infect Dis (2009) 1.02
Immunophenotypic patterns of CD8+ T cell subsets expressing CD8alphaalpha and IL-7Ralpha in viremic, aviremic and slow progressor HIV-1-infected subjects. Clin Immunol (2007) 0.99
De novo infection and propagation of wild-type Hepatitis C virus in human T lymphocytes in vitro. J Gen Virol (2006) 0.98
Functional T cell subsets contribute differentially to HIV peptide-specific responses within infected individuals: correlation of these functional T cell subsets with markers of disease progression. Clin Immunol (2007) 0.98
Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation. J Immunol (2011) 0.98
Expression and release of angiopoietin-1 from human neutrophils: intracellular mechanisms. Growth Factors (2009) 0.97
Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection. Hepatology (2004) 0.96
Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data. AIDS (2011) 0.96
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. J Virol (2004) 0.93
Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J Immunol (2009) 0.93
IL-21 enhances NK cell functions and survival in healthy and HIV-infected patients with minimal stimulation of viral replication. J Leukoc Biol (2010) 0.93
HIV Gag p24 specific responses secreting IFN-gamma and/or IL-2 in treatment-naïve individuals in acute infection early disease (AIED) are associated with low viral load. Clin Immunol (2009) 0.91
Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol (2012) 0.91
HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: implications for enhanced viral replication. J Infect Dis (2010) 0.91
Altruism motivates participation in a therapeutic HIV vaccine trial (CTN 173). AIDS Care (2010) 0.91
Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV infection. J Infect Dis (2002) 0.90
Efficient BST2 antagonism by Vpu is critical for early HIV-1 dissemination in humanized mice. Retrovirology (2013) 0.90
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS (2005) 0.89
Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS (2008) 0.89
The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection. AIDS (2016) 0.89
The colocalization potential of HIV-specific CD8+ and CD4+ T-cells is mediated by integrin β7 but not CCR6 and regulated by retinoic acid. PLoS One (2012) 0.88
Clinical features of acute retroviral syndrome differ by route of infection but not by gender and age. J Acquir Immune Defic Syndr (2002) 0.88
The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation. Cancer Res (2009) 0.88
Mind the gap: lack of association between KIR3DL1*004/HLA‐Bw4-induced natural killer cell function and protection from HIV infection. J Infect Dis (2010) 0.88
Potential role of IL-18 in the immunopathogenesis of AIDS, HIV-associated lipodystrophy and related clinical conditions. Curr HIV Res (2010) 0.87
Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients. HIV Clin Trials (2005) 0.87
Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy. HIV Clin Trials (2003) 0.86
The PKR activator, PACT, becomes a PKR inhibitor during HIV-1 replication. Retrovirology (2013) 0.86
Role of interleukin-18 in the development and pathogenesis of AIDS. AIDS Rev (2009) 0.86
Persistence of high levels of blood soluble human leukocyte antigen-G is associated with rapid progression of HIV infection. AIDS (2009) 0.85
Changes in function of HIV-specific T-cell responses with increasing time from infection. Viral Immunol (2010) 0.85
Variability in the PR and RT genes of HIV-1 isolated from recently infected subjects. Antivir Chem Chemother (2004) 0.85
Transcriptional profiling reveals molecular signatures associated with HIV permissiveness in Th1Th17 cells and identifies peroxisome proliferator-activated receptor gamma as an intrinsic negative regulator of viral replication. Retrovirology (2013) 0.85
Regulatory T cells in HIV infection: can immunotherapy regulate the regulator? Clin Dev Immunol (2012) 0.85
T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers. AIDS Res Ther (2011) 0.84
siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals. J Clin Immunol (2009) 0.83
The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90. PLoS One (2009) 0.82
Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire. AIDS (2011) 0.82
Assessment of longitudinal changes in HIV-specific effector activity in subjects undergoing untreated primary HIV infection. AIDS (2004) 0.82
Long-term immunosuppression with anti-CD25 monoclonal antibodies in heart transplant patients with chronic kidney disease. J Heart Lung Transplant (2009) 0.82
Identifying the early post-HIV antibody seroconversion period. J Infect Dis (2011) 0.82
Drug resistance mutations and the cellular immune response: a valuable synergy for the development of novel immune therapies. Curr Opin HIV AIDS (2007) 0.82
Temporal effect of HLA-B*57 on viral control during primary HIV-1 infection. Retrovirology (2013) 0.81
Near full-length genomic analysis of a novel subtype A1/C recombinant HIV type 1 isolate from Canada. AIDS Res Hum Retroviruses (2008) 0.81
Short communication: human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy. AIDS Res Hum Retroviruses (2012) 0.81
Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells. J Virol (2009) 0.81
Characterization of FGF receptor expression in human neutrophils and their contribution to chemotaxis. Am J Physiol Cell Physiol (2011) 0.81
Angiopoietin-1 but not angiopoietin-2 induces IL-8 synthesis and release by human neutrophils. J Cell Physiol (2012) 0.81
Elevated Abundance, Size, and MicroRNA Content of Plasma Extracellular Vesicles in Viremic HIV-1+ Patients: Correlations With Known Markers of Disease Progression. J Acquir Immune Defic Syndr (2015) 0.81
Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series. Am J Hematol (2008) 0.80
Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes. Vaccine (2010) 0.80
Autologous HIV-1 clade-B Nef peptides elicit increased frequency, breadth and function of CD8+ T-cells compared to consensus peptides. PLoS One (2012) 0.80